Entresto (sacubitril/valsartan) is a prescription medication used to treat heart failure in adults. It is a combination of two medications: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin receptor blocker (ARB).
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and ankles. Entresto works by inhibiting the action of neprilysin, an enzyme that breaks down substances called natriuretic peptides, which help relax and widen blood vessels. By inhibiting neprilysin, Entresto increases the levels of natriuretic peptides, which helps improve blood flow and reduce the workload on the heart. It also works by blocking the action of angiotensin II, a hormone that narrows blood vessels and increases blood pressure, which can help reduce the risk of heart attacks and stroke.
The recommended dose of Entresto is 24/26 mg twice daily. The dose may be increased to 49/51 mg twice daily in patients who tolerate the lower dose and continue to have symptoms of heart failure. Entresto is typically taken once or twice a day with or without food.
Entresto is used in adults with heart failure with reduced ejection fraction (HFrEF), which means that the heart is not pumping as well as it should. It is usually used in combination with other heart failure medications.
The cost of Entresto can vary depending on the pharmacy and the patient’s insurance coverage. It is important to check with your healthcare provider or pharmacist for the most up-to-date pricing information.
Entresto can cause side effects, including dizziness, low blood pressure, cough, and kidney problems. It can also increase the risk of angioedema (a serious allergic reaction that can cause swelling of the face, lips, tongue, and throat). It is important to discuss the potential risks and benefits of Entresto with your healthcare provider before starting treatment.
References:
- Entresto (sacubitril/valsartan) prescribing information. Novartis Pharmaceuticals Corporation. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000lbl.pdf
- Heart failure with reduced ejection fraction (HFrEF). American Heart Association. Available at: https://www.heart.org/en/health-topics/heart-failure/about-heart-failure/heart-failure-with-reduced-ejection-fraction-hfref
- Patel, R. and Sipahimalani, A. (2019). Sacubitril/Valsartan (Entresto): A Review of Its Use in Heart Failure with Reduced Ejection Fraction. Drugs, 79(12), 1297-1315.